+ Watch OCLS
on My Watchlist
The Company has developed and it manufactures and markets, a family of products intended to prevent and treat infections in chronic and acute wounds.
Oculus has continued their choppy three year decline of late with a recent acceleration of downward momentum after the last earnings report. While sales were typically disappointing and showed a foreboding sequential decline in Innovacyn revenues, I think the real pressure on the stock came from the company's declared intention to engineer a reverse split to maintain their Nasdaq listing.Playing Oculus for a rebound is a risky game that has already cost me the equivalent of all the points I've made on my multiple correct calls. I don't have much respect for the technology here but I have seen enough manipulated spikes in this stock to make it difficult to resist at depressed prices.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions